Twist Bioscience Corp SEC filings TWST
Twist Bioscience Corp has 1,001 filings in SEC EDGAR's recent list, going back to Oct 4, 2022. Its latest annual report, Form ARS, was filed on Jan 6, 2026 for the period ended Sep 30, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 3, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 19, 2026 (other events). The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Aug 19, 2026 | Aug 19, 2026 |
| 424B7 | Filing | Aug 19, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 19, 2026 | Aug 18, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Aug 5, 2026 | Aug 4, 2026 |
| 424B5 | Prospectus supplement | Aug 5, 2026 | — |
| 424B5 | Prospectus supplement | Aug 4, 2026 | — |
| 10-Q | Quarterly report | Aug 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2026 | Aug 3, 2026 |
| S-3ASR | Automatic shelf registration | Jun 18, 2026 | — |
| 10-Q | Quarterly report | May 4, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 4, 2026 | May 4, 2026 |
| UPLOAD | Letter from the SEC | Mar 5, 2026 | — |
| CORRESP | Letter to the SEC | Feb 26, 2026 | — |
| 10-Q/A | Amended quarterly report | Feb 26, 2026 | Dec 31, 2025 |
| UPLOAD | Letter from the SEC | Feb 19, 2026 | — |
| 424B7 | Filing | Feb 17, 2026 | — |
| 8-K |
Current report
Unregistered share sale, Other events
|
Feb 17, 2026 | Feb 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Feb 6, 2026 | Feb 5, 2026 |
| 10-Q | Quarterly report | Feb 2, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 2, 2026 | Feb 2, 2026 |
| 8-K |
Current report
Results of operations
|
Jan 12, 2026 | Jan 12, 2026 |
| ARS | Annual report to shareholders | Jan 6, 2026 | Sep 30, 2025 |
| DEF 14A | Proxy statement | Jan 6, 2026 | Feb 5, 2026 |
| 10-K | Annual report | Nov 17, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2025 | Nov 14, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 6, 2025 | Aug 5, 2025 |
| 10-Q | Quarterly report | Aug 4, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2025 | Aug 4, 2025 |
| 10-Q | Quarterly report | May 5, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Material agreement, Results of operations, Regulation FD disclosure
|
May 5, 2025 | May 2, 2025 |
| S-8 | Employee stock plan registration | Feb 12, 2025 | — |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Feb 11, 2025 | Feb 5, 2025 |
| 10-Q | Quarterly report | Feb 3, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 3, 2025 | Feb 3, 2025 |
| ARS | Annual report to shareholders | Jan 6, 2025 | Jan 6, 2025 |
| DEF 14A | Proxy statement | Jan 6, 2025 | Jan 6, 2025 |
| PRE 14A | Preliminary proxy statement | Dec 26, 2024 | Dec 26, 2024 |
| S-8 | Employee stock plan registration | Nov 18, 2024 | — |
| 10-K | Annual report | Nov 18, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 18, 2024 | Nov 18, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 15, 2024 | Oct 8, 2024 |
| 10-Q | Quarterly report | Aug 2, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 2, 2024 | Aug 2, 2024 |
| 10-Q | Quarterly report | May 2, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 2, 2024 | May 2, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Feb 7, 2024 | Feb 6, 2024 |
| 10-Q | Quarterly report | Feb 2, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Feb 2, 2024 | Feb 2, 2024 |
| ARS | Annual report to shareholders | Jan 5, 2024 | Sep 30, 2023 |
| DEF 14A | Proxy statement | Jan 5, 2024 | Feb 6, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 5, 2024 | Jan 5, 2024 |
| S-8 | Employee stock plan registration | Nov 21, 2023 | — |
| 10-K | Annual report | Nov 21, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 17, 2023 | Nov 17, 2023 |
| S-8 | Employee stock plan registration | Aug 25, 2023 | — |
| 10-Q | Quarterly report | Aug 7, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Aug 4, 2023 | Aug 3, 2023 |
| 8-K/A |
Amended current report
Exit or restructuring costs
|
Aug 4, 2023 | May 3, 2023 |
| S-3ASR | Automatic shelf registration | Jun 5, 2023 | — |
| 10-K/A | Amended annual report | Jun 5, 2023 | Sep 30, 2022 |
| 8-K |
Current report
Officer or director change
|
May 23, 2023 | May 23, 2023 |
| 10-Q | Quarterly report | May 8, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs
|
May 5, 2023 | May 3, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 28, 2023 | Mar 23, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Feb 8, 2023 | Feb 7, 2023 |
| 10-Q | Quarterly report | Feb 7, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Feb 3, 2023 | Feb 3, 2023 |
| DEF 14A | Proxy statement | Jan 6, 2023 | Feb 7, 2023 |
| S-8 | Employee stock plan registration | Nov 28, 2022 | — |
| 10-K | Annual report | Nov 28, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Nov 18, 2022 | Nov 17, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 18, 2022 | Nov 18, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 16, 2022 | Nov 15, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 26, 2022 | Oct 25, 2022 |
Showing 74 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TWST (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1581280
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.